Home
overview

This conference has already taken place.  For information on the 2010 event, please click on the link below:

 

COPD: Novel Therapeutics and Management Strategies 2010

 


For information about the 2007 Asthma & COPD conference, please see below...

  

 

OUR EXPERT PANEL OF SPEAKERS INCLUDES:

• Dr Chris Compton, Executive Director Clinical R&D, Pfizer
 Dr Craig S. Conoscenti, Senior Associate Director, Medical Affairs, Boehringer-Inglehiem
 Dr Malcolm Johnson, Global Director, Respiratory Science, GlaxoSmithKline
• Dr Sandy Goldman, Director, Respiratory Disease, Inflammation, Wyeth
• Stephen Stenglein, Clinical & Regulatory Affairs, Novartis
• Theodore Reiss, Executive Director, Respiratory & Allergy, Merck
• Thomas Eichholtz, Director of Discovery Medicine, Respiratory & Inflammation Research Area, AstraZeneca
• Dr Fred Bode, Associate Clinical Director, F. Hoffmann-La Roche
 Dr Kevin Bacon, Founder, CSO and Head of Research & Development, Actimis Pharmaceuticals
• Dr Christopher Molloy, Senior Research Fellow & Team Leader, Inflammation & Pulmonary Disease, Johnson & Johnson
• Dr Mick Hunter, Director of Drug Discovery, Oxagen
• Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana
• Dr Woodruff Emlen, CEO, Taligen Therapeutics
• Dr Göran Tornling, Vice President & Chief Medical Officer, Biolipox
• Dr Paolo Renzi, Chief Scientific Officer, Topigen Pharmaceuticals
• Peter Kiener D.Phil, Senior Vice President, Research, MedImmune
• Dr Charles R Penn, Chief Operating Officer, Syntaxin

The conference will be chaired by;
• Dr Michael Rudolf, Consultant Respiratory Physician, Ealing Hospital and Past Chairman, British Thoracic Society COPD Consortium
• Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust


If you attend one respiratory conference this year this should be the one! Nowhere else will you find such a diverse speaker line- up, mix of topics and in-depth coverage of the industry!

BENEFITS OF ATTENDING ASTHMA & COPD

GAIN a valuable insight into the current pipeline developments in the respiratory arena
IDENTIFY new drug developments and concepts
REVIEW the clinical endpoints that are currently being accepted
EXAMINE the development and use of biomarkers in Asthma & COPD
HEAR case studies from the world leaders in respiratory drug discovery

WHO SHOULD ATTEND ASTHMA AND COPD

You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:

  • Respiratory Science
  • Research & Development
  • Inflammation
  • Clinical & Regulatory Affairs
  • Drug Discovery
  • Respiratory Illness
  • Inhalation Drug Delivery
  • Project Management
  • Preclinical Development
  • Portfolio Management
  • Marketing
 

WHO WILL YOU MEET AT ASTHMA & COPD?

A sample of the companies already in attendance includes:

 

 

  • Abbot Laboratories
  • Actimis
  • Activaero
  • Almirall
  • ALTANA
  • Amgen
  • ARGENTA DISCOVERY
  • Astellas Pharma
  • Battelle
  • Bespak
  • Biolipox
  • Boehringer Ingelheim
  • CRS Clinical Research Services Andernach
  • Cyto Kinetics Inc
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • i3 Research
  • Imperial Innovations
  • INDRA
  • Johnson & Johnson PRD
  • Medimmune
  • Merck Research Laboratories
  • Merck Serono
  • Mundipharma
  • Novartis
  • Orion Pharma
  • Oxagen
  • Pfizer
  • Pharma Bio-Research Group BV
  • Sanofi-Aventis
  • Syntaxin
  • Taligen Therapeutics
  • Teva
  • Topigen Pharmaceuticals
  • University College London Medical School
  • Wood Mackenzie
  • Wyeth
  • VIASYS Healthcare
  • Vitalograph
 

“Great speaker diversity – topics & research”
Kim Kuebler, Medical Scientist, Boehringer-Ingelheim

It is estimated that the global annual sales in the asthma and COPD market are due to increase by over $10 billion US dollars within the next 5 years and then remain flat thereafter. Will you make use of this transforming market & increasing potential before it’s too late?

Through a series of case studies from the leading pharmaceutical companies SMi’s 3rd annual conference on Asthma & COPD will explore the new drugs in the R&D pipeline. The conference will examine the mortality levels in asthma and COPD, inspect the emerging novel treatments and drug therapies and highlight the development and use of biomarkers through to the use of clinical endpoint in Asthma & COPD.

This is your exclusive opportunity to benchmark your company by hearing from the industry leaders already at the forefront of this dynamic market.

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

Michael Rudolf

Michael Rudolf, Chairman, British Thoracic Society

Michael Rudolf

Michael Rudolf, Consultant Respiratory Physician and Past Chairman British Thoracic Society COPD Consortium, Ealing Hospital

9:10 THE GLOBAL ASTHMA AND COPD MARKET

Dr Craig Conoscenti

Dr Craig Conoscenti, Senior Associate Director, Medical Affairs, Boehringer Ingelheim

  •  Increased disease awareness
  • Pediatric asthma sector
  • Ageing population susceptible to COPD
  • Treatment cost analysis
  • Future market growth

  • 9:50 ANALYZING THE CURRENT AND FUTURE TRENDS

    Paljit Mudhar

    Paljit Mudhar, Industry Analyst, Frost and Sullivan

  • The story so far
  • Market Challenges
  • Drivers
  • Main players
  • What’s next (technologies / competition)
  • 10:30 Morning Coffee

    10:50 DEVELOPMENT AND PRECLINICAL CHARACTERIZATION

    Dr Sandy Goldman

    Dr Sandy Goldman, Director, Respiratory Disease, Inflammation, Wyeth

  • Rationale for targeting IL-13 in Asthma
  • Development of a humanized neutralizing antibody against IL-13
  • Preclinical testing of anti-IL-13 therapy in models of respiratory disease

  • 11:30 SMALL MOLECULE CRTH2 ANTAGONISTS AS

    Kevin Bacon

    Kevin Bacon, Founder, Chief Scientific Officer & Head, Research & Development, Actimis Pharmaceuticals

  • An overview of the role of CRTH2 in allergy and immunity
  • Small molecule antagonists to CRTH2; Challenges of chemistry
  • In vivo efficacy of CRTH2 antagonists in animal models of allergic disease
  • Pre-clinical and clinical development of CRTH2 antagonists

  • 12:10 TECHNICAL SHOWCASE

  • Biophysical Aspects of Lung deposition of inhaled Aerosols
  • Patients' Breathing: Deposition not only depends on particle size
  • Targeting of Drugs to different lung regions
  • Pulmonary Drug Delivery in Asthma and COPD
  • Benefits of controlled inhalation through the drug development process
  • Axel Fischer

    Axel Fischer, Managing Director, Activaero

    Gerhard Scheuch

    Gerhard Scheuch, Chief Executive Officer, Activaero

    12:20 Networking Lunch

    13:20 ROLE OF LEUKOCYTE PROTEASES IN RESPIRATORY DISEASES

    Chris Molloy

    Chris Molloy, Sr. Research Fellow and Team Leader, Inflammation & Pulmonary Diseases, Johnson & Johnson

  • Overview of the role of specific leukocyte proteases in asthma and COPD
  • Serine proteases as small molecule drug targets
  • Novel dual inhibitors of chymase and cathepsin G
  • Tryptase inhibitors in atopic diseases
  • Structure-based drug design

  • 14:00 APPLYING ANTISENSE TO THE THERAPY OF ASTHMA AND COPD

    Dr Paolo Renzi

    Dr Paolo Renzi, Chief Scientific Officer, Topigen Pharmaceuticals Inc

  • Administration and cellular uptake of oligonucleotides in the lungs
  • Rationale for using a multitarget approach in asthma and COPD
  • Preclinical results with TPI-ASM8 and TPI-1100
  • Results with TPI-ASM8 in humans
  • 14:40 SUPPRESSING MUCUS DEVELOPMENT IN RESPIRATORY DISEASE

    Dr Charles R Penn

    Dr Charles R Penn, Chief Operating Officer, Syntaxin

  • Role of mucus in respiratory disease
  • Mechanisms for mucus production
  • A protein pharmacophore that inhibits cell secretion
  • Inhibition of mucus production
  • Summary and conclusions
  • 15:20 Afternoon Tea

    15:40 AIRWAY REMODELING IN PULMONARY FIBROSIS

    Professor Geoffrey Laurent

    Professor Geoffrey Laurent, Director, Centre For Respiratory Research

    16:20 EMERGING NOVEL TREATMENTS

    Dr Woodruff Emlen

    Dr Woodruff Emlen, CEO, Taligen Therapeutics

  • Review of the role of complement in inflammation
  • Therapeutic approaches to controlling complement activation
  • Role of complement in asthma
  • New therapeutics for asthma
  • 17:00 FROM BENCH TO BEDSIDE

    Dr Chris Compton

    Dr Chris Compton, Executive Director Clinical R & D, Pfizer

    Dr Chris Compton

    Dr Chris Compton, Executive Director Clinical R & D, Pfizer

    17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Neil Barnes

    Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust

    9:10 REDUCING MORTALITY IN COPD

    Dr Malcolm Johnson

    Dr Malcolm Johnson, Global Director, Respiratory Science, Respiratory Medicines Development Centre, GlaxoSmithKline

  • COPD is the only chronic disease where the incidence is increasing and is predicted to be the third cause of mortality by 2020
  • COPD is both an airways and a systemic disease, associated with co-morbidities.
  • To date, only non-pharmacological interventions (eg smoking cessation, LTOT) have been shown to reduce mortality in COPD
  • Data from the TORCH and INSPIRE studies indicate that Seretide (LABA/ICS combination therapy) provides a survival benefit in COPD patients
  • The underlying mechanisms of this effect may provide insights into future targets to improve the mortality risk in COPD
  • 9:50 DEVELOPMENT AND USE OF BIOMARKERS IN ASTHMA & COPD TO HELP ACCELERATE DRUG DEVELOPMENT

  • Biomarkers can accelerate early Stop/Go decisions in Asthma & COPD
  • Biomarkers are also important in predicting long term outcomes with short term studies
  • Disease modification remains a long term challenge in both Asthma and COPD and new insights from biomarkers can help determine new therapeutic strategies
  • Biomarkers remain important tools for diseases segmentation, reclassification and patient stratification in both Asthma & COPD
  • Examples of such strategies will be presented during the conference
  • Dr Harsukh Parmar

    Dr Harsukh Parmar, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy Area, AstraZeneca

    Dr Thomas Eichholtz

    Dr Thomas Eichholtz, Director of Discovery Medicine, Astrazeneca

    10:30 Morning Coffee

    10:50 DATA QUALITY THROUGH STANDARDIZATION

    Philip Geronimo

    Philip Geronimo, Senior Education Director, VIASYS

    11:30 BIOMARKERS OF INFLAMMATION IN ASTHMA & COPD

    Theodore Reiss

    Theodore Reiss, Executive Director, Respiratory & Allergy, Merck Research Laboratories*

    12:10 LUNG FUNCTION PARAMETERS AND INTERPRETATION

    Dr Fred Bode

    Dr Fred Bode, Associate Clinical Director, Medical Science, Hoffmann-La Roche

  • FEV1 remains in-sensitive to small airways changes
  • Newer tests have high technical requirements
  • 12:50 Networking Lunch

    13:50 QUALITY CONTROL OF SPIROMETRY IN GLOBAL STUDIES

    Aleck Harrison

    Aleck Harrison, Consultant Clinical Scientist, AJH Partners

  • Over reading systems the plus and minus
  • Identifying abnormalities and their cause
  • Case studies
  • 14:30 PATIENT REPORTED OUTCOMES AS COMPARED TO LUNG FUNCTION OUTCOMES

    Dr Göran Tornling

    Dr Göran Tornling, Vice President and Chief Medical Officer, Biolipox AB

  • Patient reported outcomes and lung function outcomes are not interchangeable
  • Should exacerbations be defined from patient reported outcomes, lung function or intervention?
  • The patient’s perspective
  • The physician’s perspective
  • The regulator’s perspective
  • 15:10 Afternoon Tea

    15:30 CRTH2 A NOVEL TARGET FOR ASTHMA AND ALLERGY

    Mick Hunter

    Mick Hunter, Director, Drug Discovery, Oxagen

    • Role of CRTH2 in allergy inflammation
    • Oxagen CRTH2 antagonists
    • Antagonists of CRTH2 as an approach to treat disease
    • Clinical development status

    16:10 USE OF CLINICAL ENDPOINTS OTHER THAN LUNG FUNCTION IN COPD CLINICAL STUDIES

    Dr Shahin Sanjar

    Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana Pharma

  • COPD is predominantly regarded as a chronic airway disease and so most clinical studies focus on measurement of lung function as a primary endpoint
  • It is now recognized that COPD patients suffer co-morbidities such as CV, metabolic, GI and orthopaedic disease, which may be important contributors to the overall poor health status of patients
  • Treatment of airway disease remains the gold standard for treating COPD.  However, targeting the major co-morbidities may be critical in improving health status of COPD patients
  • Persistent and/or latent pulmonary hypertension is recognized as a feature in many COPD patients, which can have a debilitating effect on physical activity in these patients
  • Alternative clinical endpoints may be better predictors of disease progression in COPD
  • 16:50 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Steroid Insensitivity in Severe Asthma and COPD
    Workshop

    Steroid Insensitivity in Severe Asthma and COPD

    The Hatton, at etc. venues
    24th April 2007
    London, United Kingdom

    The Law Society's Hall

    113 Chancery Lane
    London WC2A 1PL
    United Kingdom

    The Law Society's Hall

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.